30 to 40 % of mental illnesses in UAE are schizophrenia-related.
Dr. Amin said 60 per cent of patients are not fully cured because they don't follow the treatment strictly. About 80 per cent of the patients don't go directly to a doctor on first symptoms. Patients of bipolar disorder experience episodes of mania and depression alongside periods of normal mood, with symptoms ranging from trouble concentrating and sleep disturbance to high-risk behavior and thoughts of suicide. Dr Amin said:" Quetiapine Sustained Release from AstraZeneca enhances compliance. Also, the once daily dosage makes it easier on the patient to comply with the treatment, eliminating drug fluctuation in the blood leading to positive results".Quetiapine Sustained Release is approved in the US and 25 other countries for the treatment of schizophrenia in adult patients and for maintenance treatment of schizophrenia in adult patients. It was launched in the US in 2007 and earlier this year AstraZeneca announced the submission of regulatory applications in both the US and European Union for Quetiapine Fumarate in the treatment of manic episodes associated with bipolar disorder, and treatment of depressive episodes associated with bipolar disorder. Quetiapine Sustained Release tablets have been approved for the treatment of Schizophrenia in the UAE and Bahrain. Quetiapine has been prescribed to more than 22 million patients worldwide. It is approved in 88 countries for the treatment of schizophrenia, in 79 countries for the treatment of bipolar mania, and in 11 countries including the US for the treatment of bipolar depression. . 2009 Al Bawaba (www.albawaba.com)
2009 Al Bawaba (Albawaba.com)
Provided by Syndigate.info an Albawaba.com company
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 31, 2009|
|Previous Article:||Business Software Alliance opens nominations for 2009 Pan Arab IPR Media Awards.|
|Next Article:||Arab Banking Corporation (ABC) announces nine-month profit of $80 million.|